Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bio-Techne ( (TECH) ) has issued an update.
Bio-Techne reported its fourth quarter fiscal 2025 results, highlighting a 3% organic revenue increase to $317.0 million and a full-year organic revenue growth of 5% to $1.2 billion. Despite a decrease in GAAP EPS to ($0.11) from $0.25 a year ago, adjusted EPS rose to $0.53 from $0.49. The company announced the divestiture of its Exosome Diagnostics business to focus on high-growth areas, which is expected to enhance profitability. The Protein Sciences segment showed strong growth, while the Diagnostics and Spatial Biology segment faced challenges due to unfavorable product mix.
The most recent analyst rating on (TECH) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Outperform.
Bio-Techne’s overall stock score is supported by strong financial performance and strategic resilience highlighted in the earnings call. While technical indicators and high valuation present some caution, the company’s growth prospects and financial management remain robust.
To see Spark’s full report on TECH stock, click here.
More about Bio-Techne
Bio-Techne Corporation operates in the biotechnology industry, focusing on providing specialized proteins, immunoassays, antibodies, and reagents for biopharma and academic research communities. The company also offers spatial biology products and exosome-based diagnostics for various pathologies, including prostate cancer.
Average Trading Volume: 2,376,559
Technical Sentiment Signal: Sell
Current Market Cap: $8.6B
For a thorough assessment of TECH stock, go to TipRanks’ Stock Analysis page.